America weighing drug licensing with China

The United States is currently studying the implementation of new rules for American pharmaceutical companies' investments in the Chinese market. These rules would allow most licensing deals for drugs with Chinese companies, with the exception of medications related to pathogens or biotechnologies that could be used as weapons. The aim of these regulations is to enable American companies to invest in promising drugs developed by Chinese firms and to strengthen the list of drugs in development, while trying to strike a balance between national security and promoting economic cooperation. The rules remain provisional and may change, as the reaction of the Trump administration and lawmakers is being monitored. It is believed that these measures will curb some of the restrictions previously imposed on engagement with China in the pharmaceutical and biotechnology sectors.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل